Role of monocarboxylate transporters in drug delivery to the brain

Current Pharmaceutical Design

Volumn 20, Issue 10, 2014, Pages 1487-1498

  Vijay, Nisha ^a   Morris, Marilyn E ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

Brain; Lactate; Monocarboxylate transporters; hydroxybutyrate

Indexed keywords

4 HYDROXYBUTYRIC ACID; ATORVASTATIN; BUMETANIDE; GABAPENTIN; GABAPENTIN ENACARBIL; GLUCOSE; KETONE BODY; LACTIC ACID; MONOCARBOXYLATE TRANSPORTER; MONOCARBOXYLATE TRANSPORTER 1; MONOCARBOXYLATE TRANSPORTER 10; MONOCARBOXYLATE TRANSPORTER 2; MONOCARBOXYLATE TRANSPORTER 3; MONOCARBOXYLATE TRANSPORTER 4; MONOCARBOXYLATE TRANSPORTER 6; MONOCARBOXYLATE TRANSPORTER 8; NATEGLINIDE; SALICYLIC ACID; SIMVASTATIN; SODIUM COUPLED MONOCARBOXYLATE TRANSPORTER; UNCLASSIFIED DRUG; VALPROIC ACID;

ASTROCYTE; BLOOD BRAIN BARRIER; BRAIN; BRAIN CORTEX; BRAIN TUMOR; CEREBELLUM; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DISPOSITION; ELECTRON MICROSCOPY; ENDOTHELIUM CELL; ENZYME SPECIFICITY; ERYTHROCYTE; GENE EXPRESSION; GLUCOSE UTILIZATION; GLYCOLYSIS; HIPPOCAMPUS; HUMAN; HYPOTHALAMUS; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INTESTINE ABSORPTION; MEMBRANE PERMEABILITY; NONHUMAN; ORGAN; POSTSYNAPTIC MEMBRANE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PURKINJE FIBER; REVIEW; SEQUENCE HOMOLOGY; UPREGULATION;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; DRUG DELIVERY SYSTEMS; HUMANS; MONOCARBOXYLIC ACID TRANSPORTERS; PHARMACEUTICAL PREPARATIONS;

EID: 84897412061     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113199990462     Document Type: Review

References (125)

1. Poole RC, Halestrap AP. Transport of lactate and other monocarboxylates across mammalian plasma membranes. Am J Physiol 1993; 264: C761-82.
2. Juel C. Lactate-proton cotransport in skeletal muscle. Physiol Rev 1997; 77: 321-58.
3. Halestrap AP, Price NT. The proton-linked monocarboxylate transporter (MCT) family: structure, function and regulation. Biochem J 1999; 343 Pt 2: 281-99.
4. Jackson VN, Halestrap AP. The kinetics, substrate, and inhibitor specificity of the monocarboxylate (lactate) transporter of rat liver cells determined using the fluorescent intracellular pH indicator, 2', 7'-bis(carboxyethyl)-5(6)-carboxyfluorescein. J Biol Chem 1996; 271: 861-8.
5. Coady MJ, Chang MH, Charron FM, et al. The human tumour suppressor gene SLC5A8 expresses a Na+-monocarboxylate cotransporter. J Physiol 2004; 557: 719-31.
6. Gopal E, Fei YJ, Sugawara M, et al. Expression of slc5a8 in kidney and its role in Na(+)-coupled transport of lactate. J Biol Chem 2004; 279: 44522-32.
7. Srinivas SR, Gopal E, Zhuang L, et al. Cloning and functional identification of slc5a12 as a sodium-coupled low-affinity transporter for monocarboxylates (SMCT2). Biochem J 2005; 392: 655-64.
8. Halestrap AP, Meredith D. The SLC16 gene family-from monocarboxylate transporters (MCTs) to aromatic amino acid transporters and beyond. Pflugers Arch 2004; 447: 619-28.
9. Pierre K, Pellerin L. Monocarboxylate transporters in the central nervous system: distribution, regulation and function. J Neurochem 2005; 94: 1-14.
10. Wang Q, Darling IM, Morris ME. Transport of gammahydroxybutyrate in rat kidney membrane vesicles: Role of monocarboxylate transporters. J Pharmacol Exp Ther 2006; 318: 751-61.
11. Wang Q, Lu Y, Morris ME. Monocarboxylate transporter (MCT) mediates the transport of gamma-hydroxybutyrate in human kidney HK-2 cells. Pharm Res 2007; 24: 1067-78.
12. Wang Q, Morris ME. The role of monocarboxylate transporter 2 and 4 in the transport of gamma-hydroxybutyric acid in mammalian cells. Drug Metab Dispos 2007; 35: 1393-9.
13. Cui D, Morris ME. The drug of abuse gamma-hydroxybutyrate is a substrate for sodium-coupled monocarboxylate transporter (SMCT) 1 (SLC5A8): characterization of SMCT-mediated uptake and inhibition. Drug Metab Dispos 2009; 37: 1404-10.
14. Deuticke B. Monocarboxylate transport in erythrocytes. J Membr Biol 1982; 70: 89-103.
15. Halestrap AP. Transport of pyruvate nad lactate into human erythrocytes. Evidence for the involvement of the chloride carrier and a chloride-independent carrier. Biochem J 1976; 156: 193-207.
16. De Bruijne AW, Vreeburg H, Van Steveninck J. Kinetic analysis of L-lactate transport in human erythrocytes via the monocarboxylatespecific carrier system. Biochim Biophys Acta 1983; 732: 562-8.
17. Poole RC, Sansom CE, Halestrap AP. Studies of the membrane topology of the rat erythrocyte H+/lactate cotransporter (MCT1). Biochem J 1996; 320 (Pt 3): 817-24.
18. Juel C, Halestrap AP. Lactate transport in skeletal muscle-role and regulation of the monocarboxylate transporter. J Physiol 1999; 517 (Pt 3): 633-42.
19. Enoki T, Yoshida Y, Lally J, Hatta H, Bonen A. Testosterone increases lactate transport, monocarboxylate transporter (MCT) 1 and MCT4 in rat skeletal muscle. J Physiol 2006; 577: 433-43.
20. Chenal J, Pellerin L. Noradrenaline enhances the expression of the neuronal monocarboxylate transporter MCT2 by translational activation via stimulation of PI3K/Akt and the mTOR/S6K pathway. J Neurochem 2007; 102: 389-97.
21. Wilson MC, Meredith D, Fox JE, Manoharan C, Davies AJ, Halestrap AP. Basigin (CD147) is the target for organomercurial inhibition of monocarboxylate transporter isoforms 1 and 4: the ancillary protein for the insensitive MCT2 is EMBIGIN (gp70). J Biol Chem 2005; 280: 27213-21.
22. Kim CM, Goldstein JL, Brown MS. cDNA cloning of MEV, a mutant protein that facilitates cellular uptake of mevalonate, and identification of the point mutation responsible for its gain of function. J Biol Chem 1992; 267: 23113-21.
23. Jackson VN, Price NT, Halestrap AP. cDNA cloning of MCT1, a monocarboxylate transporter from rat skeletal muscle. Biochim Biophys Acta 1995; 1238: 193-6.
24. Carpenter L, Poole RC, Halestrap AP. Cloning and sequencing of the monocarboxylate transporter from mouse Ehrlich Lettre tumour cell confirms its identity as MCT1 and demonstrates that glycosylation is not required for MCT1 function. Biochim Biophys Acta 1996; 1279: 157-63.
25. Takanaga H, Tamai I, Inaba S, et al. cDNA cloning and functional characterization of rat intestinal monocarboxylate transporter. Biochem Biophys Res Commun 1995; 217: 370-7.
26. Garcia CK, Goldstein JL, Pathak RK, Anderson RG, Brown MS. Molecular characterization of a membrane transporter for lactate, pyruvate, and other monocarboxylates: implications for the Cori cycle. Cell 1994; 76: 865-73.
27. Broer S, Schneider HP, Broer A, Rahman B, Hamprecht B, Deitmer JW. Characterization of the monocarboxylate transporter 1 expressed in Xenopus laevis oocytes by changes in cytosolic pH. Biochem J 1998; 333 (Pt 1): 167-74.
28. de Bruijne AW, Vreeburg H, van Steveninck J. Alternativesubstrate inhibition of L-lactate transport via the monocarboxylatespecific carrier system in human erythrocytes. Biochim Biophys Acta 1985; 812: 841-4.
29. Morris ME, Felmlee MA. Overview of the proton-coupled MCT (SLC16A) family of transporters: characterization, function and role in the transport of the drug of abuse gamma-hydroxybutyric acid. AAPS J 2008; 10: 311-21.
30. Halestrap AP, Denton RM. Specific inhibition of pyruvate transport in rat liver mitochondria and human erythrocytes by alpha-cyano-4-hydroxycinnamate. Biochem J 1974; 138: 313-6.
31. Halestrap AP, Brand MD, Denton RM. Inhibition of mitochondrial pyruvate transport by phenylpyruvate and alpha-ketoisocaproate. Biochim Biophys Acta 1974; 367: 102-8.
32. Halestrap AP. The mitochondrial pyruvate carrier. Kinetics and specificity for substrates and inhibitors. Biochem J 1975; 148: 85-96.
33. Halestrap AP, Denton RM. The specificity and metabolic implications of the inhibition of pyruvate transport in isolated mitochondria and intact tissue preparations by alpha-Cyano-4-hydroxycinnamate and related compounds. Biochem J 1975; 148: 97-106.
34. Garcia CK, Brown MS, Pathak RK, Goldstein JL. cDNA cloning of MCT2, a second monocarboxylate transporter expressed in different cells than MCT1. J Biol Chem 1995; 270: 1843-9.
35. Jackson VN, Price NT, Carpenter L, Halestrap AP. Cloning of the monocarboxylate transporter isoform MCT2 from rat testis provides evidence that expression in tissues is species-specific and may involve post-transcriptional regulation. Biochem J 1997; 324 (Pt 2): 447-53.
36. Lin RY, Vera JC, Chaganti RS, Golde DW. Human monocarboxylate transporter 2 (MCT2) is a high affinity pyruvate transporter. J Biol Chem 1998; 273: 28959-65.
37. Broer S, Broer A, Schneider HP, Stegen C, Halestrap AP, Deitmer JW. Characterization of the high-affinity monocarboxylate transporter MCT2 in Xenopus laevis oocytes. Biochem J 1999; 341 (Pt 3): 529-35.
38. Halestrap AP. The monocarboxylate transporter family--Structure and functional characterization. IUBMB Life 2012; 64: 1-9.
39. Yoon H, Fanelli A, Grollman EF, Philp NJ. Identification of a unique monocarboxylate transporter (MCT3) in retinal pigment epithelium. Biochem Biophys Res Commun 1997; 234: 90-4.
40. Grollman EF, Philp NJ, McPhie P, Ward RD, Sauer B. Determination of transport kinetics of chick MCT3 monocarboxylate transporter from retinal pigment epithelium by expression in genetically modified yeast. Biochemistry 2000; 39: 9351-7.
41. Philp NJ, Yoon H, Grollman EF. Monocarboxylate transporter MCT1 is located in the apical membrane and MCT3 in the basal membrane of rat RPE. Am J Physiol 1998; 274: R1824-8.
42. Bergersen L, Johannsson E, Veruki ML, et al. Cellular and subcellular expression of monocarboxylate transporters in the pigment epithelium and retina of the rat. Neuroscience 1999; 90: 319-31.
43. Price NT, Jackson VN, Halestrap AP. Cloning and sequencing of four new mammalian monocarboxylate transporter (MCT) homologues confirms the existence of a transporter family with an ancient past. Biochem J 1998; 329 (Pt 2): 321-8.
44. Dimmer KS, Friedrich B, Lang F, Deitmer JW, Broer S. The lowaffinity monocarboxylate transporter MCT4 is adapted to the export of lactate in highly glycolytic cells. Biochem J 2000; 350 Pt 1: 219-27.
45. Manning Fox JE, Meredith D, Halestrap AP. Characterisation of human monocarboxylate transporter 4 substantiates its role in lactic acid efflux from skeletal muscle. J Physiol 2000; 529 Pt 2: 285-93.
46. Murakami Y, Kohyama N, Kobayashi Y, et al. Functional characterization of human monocarboxylate transporter 6 (SLC16A5). Drug Metab Dispos 2005; 33: 1845-51.
47. Lafreniere RG, Carrel L, Willard HF. A novel transmembrane transporter encoded by the XPCT gene in Xq13. 2. Hum Mol Genet 1994; 3: 1133-9.
48. Friesema EC, Ganguly S, Abdalla A, et al. Identification of monocarboxylate transporter 8 as a specific thyroid hormone transporter. J Biol Chem 2003; 278: 40128-35.
49. Visser WE, Friesema EC, Visser TJ. Minireview: thyroid hormone transporters: the knowns and the unknowns. Mol Endocrinol 2011; 25: 1-14.
50. Kim DK, Kanai Y, Chairoungdua A, Matsuo H, Cha SH, Endou H. Expression cloning of a Na+-independent aromatic amino acid transporter with structural similarity to H+/monocarboxylate transporters. J Biol Chem 2001; 276: 17221-8.
51. Meredith D, Christian HC. The SLC16 monocaboxylate transporter family. Xenobiotica 2008; 38: 1072-106.
52. Tonduti D, Vanderver A, Berardinelli A, et al. MCT8 Deficiency: Extrapyramidal Symptoms and Delayed Myelination as Prominent Features. J Child Neurol 2012.
53. Braun D, Kim TD, le Coutre P, Kohrle J, Hershman JM, Schweizer U. Tyrosine kinase inhibitors noncompetitively inhibit MCT8-mediated iodothyronine transport. J Clin Endocrinol Metab 2012; 97: E100-5.
54. Ganapathy V, Thangaraju M, Gopal E, et al. Sodium-coupled monocarboxylate transporters in normal tissues and in cancer. AAPS J 2008; 10: 193-9.
55. Li H, Myeroff L, Smiraglia D, et al. SLC5A8, a sodium transporter, is a tumor suppressor gene silenced by methylation in human colon aberrant crypt foci and cancers. Proc Natl Acad Sci U S A 2003; 100: 8412-7.
56. Barac-Nieto M, Murer H, Kinne R. Lactate-sodium cotransport in rat renal brush border membranes. Am J Physiol 1980; 239: F496-506.
57. Gopal E, Umapathy NS, Martin PM, et al. Cloning and functional characterization of human SMCT2 (SLC5A12) and expression pattern of the transporter in kidney. Biochim Biophys Acta 2007; 1768: 2690-7.
58. Erecinska M, Cherian S, Silver IA. Energy metabolism in mammalian brain during development. Prog Neurobiol 2004; 73: 397-445.
59. Pellerin L, Pellegri G, Martin JL, Magistretti PJ. Expression of monocarboxylate transporter mRNAs in mouse brain: support for a distinct role of lactate as an energy substrate for the neonatal vs. adult brain. Proc Natl Acad Sci U S A 1998; 95: 3990-5.
60. Robinson AM, Williamson DH. Physiological roles of ketone bodies as substrates and signals in mammalian tissues. Physiol Rev 1980; 60: 143-87.
61. Fernandez E, Medina JM. Lactate utilization by the neonatal rat brain in vitro. Competition with glucose and 3-hydroxybutyrate. Biochem J 1986; 234: 489-92.
62. Hawkins RA, Mans AM, Davis DW. Regional ketone body utilization by rat brain in starvation and diabetes. Am J Physiol 1986; 250: E169-78.
63. Bergersen L, Rafiki A, Ottersen OP. Immunogold cytochemistry identifies specialized membrane domains for monocarboxylate transport in the central nervous system. Neurochem Res 2002; 27: 89-96.
64. Pierre K, Pellerin L, Debernardi R, Riederer BM, Magistretti PJ. Cell-specific localization of monocarboxylate transporters, MCT1 and MCT2, in the adult mouse brain revealed by double immunohistochemical labeling and confocal microscopy. Neuroscience 2000; 100: 617-27.
65. Broer S, Rahman B, Pellegri G, et al. Comparison of lactate transport in astroglial cells and monocarboxylate transporter 1 (MCT 1) expressing Xenopus laevis oocytes. Expression of two different monocarboxylate transporters in astroglial cells and neurons. J Biol Chem 1997; 272: 30096-102.
66. Bouzier-Sore AK, Voisin P, Canioni P, Magistretti PJ, Pellerin L. Lactate is a preferential oxidative energy substrate over glucose for neurons in culture. J Cereb Blood Flow Metab 2003; 23: 1298-306.
67. Itoh Y, Esaki T, Shimoji K, et al. Dichloroacetate effects on glucose and lactate oxidation by neurons and astroglia in vitro and on glucose utilization by brain in vivo. Proc Natl Acad Sci U S A 2003; 100: 4879-84.
68. Suzuki A, Stern SA, Bozdagi O, et al. Astrocyte-neuron lactate transport is required for long-term memory formation. Cell 2011; 144: 810-23.
69. Pellerin L, Magistretti PJ. Glutamate uptake into astrocytes stimulates aerobic glycolysis: a mechanism coupling neuronal activity to glucose utilization. Proc Natl Acad Sci U S A 1994; 91: 10625-9.
70. Magistretti PJ, Sorg O, Yu N, Martin JL, Pellerin L. Neurotransmitters regulate energy metabolism in astrocytes: implications for the metabolic trafficking between neural cells. Dev Neurosci 1993; 15: 306-12.
71. McKenna MC, Tildon JT, Stevenson JH, Hopkins IB, Huang X, Couto R. Lactate transport by cortical synaptosomes from adult rat brain: characterization of kinetics and inhibitor specificity. Dev Neurosci 1998; 20: 300-9.
72. Bittar PG, Charnay Y, Pellerin L, Bouras C, Magistretti PJ. Selective distribution of lactate dehydrogenase isoenzymes in neurons and astrocytes of human brain. J Cereb Blood Flow Metab 1996; 16: 1079-89.
73. Gerhart DZ, Enerson BE, Zhdankina OY, Leino RL, Drewes LR. Expression of monocarboxylate transporter MCT1 by brain endothelium and glia in adult and suckling rats. Am J Physiol 1997; 273: E207-13.
74. Cremer JE, Cunningham VJ, Pardridge WM, Braun LD, Oldendorf WH. Kinetics of blood-brain barrier transport of pyruvate, lactate and glucose in suckling, weanling and adult rats. J Neurochem 1979; 33: 439-45.
75. Leino RL, Gerhart DZ, Drewes LR. Monocarboxylate transporter (MCT1) abundance in brains of suckling and adult rats: a quantitative electron microscopic immunogold study. Brain Res Dev Brain Res 1999; 113: 47-54.
76. Vannucci SJ, Simpson IA. Developmental switch in brain nutrient transporter expression in the rat. Am J Physiol Endocrinol Metab 2003; 285: E1127-34.
77. Wang Y, Guo SZ, Bonen A, et al. Monocarboxylate transporter 2 and stroke severity in a rodent model of sleep apnea. J Neurosci 2011; 31: 10241-8.
78. Moschen I, Broer A, Galic S, Lang F, Broer S. Significance of Short Chain Fatty Acid Transport by Members of the Monocarboxylate Transporter Family (MCT). Neurochem Res 2012.
79. Hanu R, McKenna M, O'Neill A, Resneck WG, Bloch RJ. Monocarboxylic acid transporters, MCT1 and MCT2, in cortical astrocytes in vitro and in vivo. Am J Physiol Cell Physiol 2000; 278: C921-30.
80. Debernardi R, Pierre K, Lengacher S, Magistretti PJ, Pellerin L. Cell-specific expression pattern of monocarboxylate transporters in astrocytes and neurons observed in different mouse brain cortical cell cultures. J Neurosci Res 2003; 73: 141-55.
81. Shawahna R, Uchida Y, Decleves X, et al. Transcriptomic and quantitative proteomic analysis of transporters and drug metabolizing enzymes in freshly isolated human brain microvessels. Mol Pharm 2011; 8: 1332-41.
82. Koehler-Stec EM, Simpson IA, Vannucci SJ, Landschulz KT, Landschulz WH. Monocarboxylate transporter expression in mouse brain. Am J Physiol 1998; 275: E516-24.
83. Pierre K, Magistretti PJ, Pellerin L. MCT2 is a major neuronal monocarboxylate transporter in the adult mouse brain. J Cereb Blood Flow Metab 2002; 22: 586-95.
84. Bergersen L, Waerhaug O, Helm J, et al. A novel postsynaptic density protein: the monocarboxylate transporter MCT2 is colocalized with delta-glutamate receptors in postsynaptic densities of parallel fiber-Purkinje cell synapses. Exp Brain Res 2001; 136: 523-34.
85. Gerhart DZ, Enerson BE, Zhdankina OY, Leino RL, Drewes LR. Expression of the monocarboxylate transporter MCT2 by rat brain glia. Glia 1998; 22: 272-81.
86. Mac M, Nalecz KA. Expression of monocarboxylic acid transporters (MCT) in brain cells. Implication for branched chain alpha-ketoacids transport in neurons. Neurochem Int 2003; 43: 305-9.
87. Pellerin L, Bergersen LH, Halestrap AP, Pierre K. Cellular and subcellular distribution of monocarboxylate transporters in cultured brain cells and in the adult brain. J Neurosci Res 2005; 79: 55-64.
88. Martin PM, Gopal E, Ananth S, et al. Identity of SMCT1 (SLC5A8) as a neuron-specific Na+-coupled transporter for active uptake of L-lactate and ketone bodies in the brain. J Neurochem 2006; 98: 279-88.
89. Kang YS, Terasaki T, Tsuji A. Acidic drug transport in vivo through the blood-brain barrier. A role of the transport carrier for monocarboxylic acids. J Pharmacobiodyn 1990; 13: 158-63.
90. Terasaki T, Takakuwa S, Moritani S, Tsuji A. Transport of monocarboxylic acids at the blood-brain barrier: studies with monolayers of primary cultured bovine brain capillary endothelial cells. J Pharmacol Exp Ther 1991; 258: 932-7.
91. Shimada A, Nakagawa Y, Morishige H, Yamamoto A, Fujita T. Functional characteristics of H+-dependent nicotinate transport in primary cultures of astrocytes from rat cerebral cortex. Neurosci Lett 2006; 392: 207-12.
92. Gopal E, Fei YJ, Miyauchi S, Zhuang L, Prasad PD, Ganapathy V. Sodium-coupled and electrogenic transport of B-complex vitamin nicotinic acid by slc5a8, a member of the Na/glucose co-transporter gene family. Biochem J 2005; 388: 309-16.
93. Morris MC, Evans DA, Bienias JL, et al. Dietary niacin and the risk of incident Alzheimer's disease and of cognitive decline. J Neurol Neurosurg Psychiatry 2004; 75: 1093-9.
94. Saheki A, Terasaki T, Tamai I, Tsuji A. In vivo and in vitro bloodbrain barrier transport of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors. Pharm Res 1994; 11: 305-11.
95. Tsuji A, Saheki A, Tamai I, Terasaki T. Transport mechanism of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors at the blood-brain barrier. J Pharmacol Exp Ther 1993; 267: 1085-90.
96. Kobayashi M, Otsuka Y, Itagaki S, Hirano T, Iseki K. Inhibitory effects of statins on human monocarboxylate transporter 4. Int J Pharm 2006; 317: 19-25.
97. Kassan M, Montero MJ, Sevilla MA. In vitro antioxidant activity of pravastatin provides vascular protection. Eur J Pharmacol 2010; 630: 107-11.
98. Barone E, Cenini G, Di Domenico F, et al. Long-term high-dose atorvastatin decreases brain oxidative and nitrosative stress in a preclinical model of Alzheimer disease: a novel mechanism of action. Pharmacol Res 2011; 63: 172-80.
99. Deguchi Y, Nozawa K, Yamada S, Yokoyama Y, Kimura R. Quantitative evaluation of brain distribution and blood-brain barrier efflux transport of probenecid in rats by microdialysis: possible involvement of the monocarboxylic acid transport system. J Pharmacol Exp Ther 1997; 280: 551-60.
100. Deguchi Y, Yokoyama Y, Sakamoto T, et al. Brain distribution of 6-mercaptopurine is regulated by the efflux transport system in the blood-brain barrier. Life Sci 2000; 66: 649-62.
101. Cundy KC, Branch R, Chernov-Rogan T, et al. XP13512 [(+/-)-1-([(alpha-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: I. Design, synthesis, enzymatic conversion to gabapentin, and transport by intestinal solute transporters. J Pharmacol Exp Ther 2004; 311: 315-23.
102. Cundy KC, Annamalai T, Bu L, et al. XP13512 [(+/-)-1-([(alphaisobutanoyloxyethoxy) carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: II. Improved oral bioavailability, dose proportionality, and colonic absorption compared with gabapentin in rats and monkeys. J Pharmacol Exp Ther 2004; 311: 324-33.
103. Cundy KC, Sastry S, Luo W, Zou J, Moors TL, Canafax DM. Clinical pharmacokinetics of XP13512, a novel transported prodrug of gabapentin. J Clin Pharmacol 2008; 48: 1378-88.
104. Maitre M. The gamma-hydroxybutyrate signalling system in brain: organization and functional implications. Prog Neurobiol 1997; 51: 337-61.
105. Mamelak M, Scharf MB, Woods M. Treatment of narcolepsy with gamma-hydroxybutyrate. A review of clinical and sleep laboratory findings. Sleep 1986; 9: 285-9.
106. Okun MS, Boothby LA, Bartfield RB, Doering PL. GHB: an important pharmacologic and clinical update. J Pharm Pharm Sci 2001; 4: 167-75.
107. Lettieri JT, Fung HL. Dose-dependent pharmacokinetics and hypnotic effects of sodium gamma-hydroxybutyrate in the rat. J Pharmacol Exp Ther 1979; 208: 7-11.
108. Palatini P, Tedeschi L, Frison G, et al. Dose-dependent absorption and elimination of gamma-hydroxybutyric acid in healthy volunteers. Eur J Clin Pharmacol 1993; 45: 353-6.
109. Ferrara SD, Zotti S, Tedeschi L, et al. Pharmacokinetics of gammahydroxybutyric acid in alcohol dependent patients after single and repeated oral doses. Br J Clin Pharmacol 1992; 34: 231-5.
110. Lettieri J, Fung HL. Improved pharmacological activity via prodrug modification: comparative pharmacokinetics of sodium gamma-hydroxybutyrate and gamma-butyrolactone. Res Commun Chem Pathol Pharmacol 1978; 22: 107-18.
111. Arena C, Fung HL. Absorption of sodium gamma-hydroxybutyrate and its prodrug gamma-butyrolactone: relationship between in vitro transport and in vivo absorption. J Pharm Sci 1980; 69: 356-8.
112. Morris ME, Hu K, Wang Q. Renal clearance of gammahydroxybutyric acid in rats: increasing renal elimination as a detoxification strategy. J Pharmacol Exp Ther 2005; 313: 1194-202.
113. Lam WK, Felmlee MA, Morris ME. Monocarboxylate transportermediated transport of gamma-hydroxybutyric acid in human intestinal Caco-2 cells. Drug Metab Dispos 2010; 38: 441-7.
114. Bhattacharya I, Boje KM. GHB (gamma-hydroxybutyrate) carriermediated transport across the blood-brain barrier. J Pharmacol Exp Ther 2004; 311: 92-8.
115. Bhattacharya I, Boje KM. Potential gamma-hydroxybutyric acid (GHB) drug interactions through blood-brain barrier transport inhibition: a pharmacokinetic simulation-based evaluation. J Pharmacokinet Pharmacodyn 2006; 33: 657-81.
116. Roiko SA, Felmlee MA, Morris ME. Brain uptake of the drug of abuse gamma-hydroxybutyric acid in rats. Drug Metab Dispos 2012; 40: 212-8.
117. Morse BL, Felmlee MA, Morris ME. gamma-Hydroxybutyrate blood/plasma partitioning: effect of physiologic pH on transport by monocarboxylate transporters. Drug Metab Dispos 2012; 40: 64-9.
118. Pinheiro C, Longatto-Filho A, Azevedo-Silva J, Casal M, Schmitt FC, Baltazar F. Role of monocarboxylate transporters in human cancers: state of the art. J Bioenerg Biomembr 2012; 44: 127-39.
119. Mathupala SP, Parajuli P, Sloan AE. Silencing of monocarboxylate transporters via small interfering ribonucleic acid inhibits glycolysis and induces cell death in malignant glioma: an in vitro study. Neurosurgery 2004; 55: 1410-9; discussion 1419.
120. Colen CB, Shen Y, Ghoddoussi F, et al. Metabolic targeting of lactate efflux by malignant glioma inhibits invasiveness and induces necrosis: an in vivo study. Neoplasia 2011; 13: 620-32.
121. Cheng C, Edin NF, Lauritzen KH, et al. Alterations of monocarboxylate transporter densities during hypoxia in brain and breast tumour cells. Cell Oncol (Dordr) 2012; 35: 217-27.
122. Cui D, Guan Y, Jang H, Wang J, Xi L, Wang Q. Expression of monocarboxylate transporter 8 mRNA in the brain tissue of rats with cerebral ischemia. J Southern Med Univ 2012; 32: 913-5.
123. Murray CM, Hutchinson R, Bantick JR, et al. Monocarboxylate transporter MCT1 is a target for immunosuppression. Nat Chem Biol 2005; 1: 371-6.
124. Ovens MJ, Davies AJ, Wilson MC, Murray CM, Halestrap AP. AR-C155858 is a potent inhibitor of monocarboxylate transporters MCT1 and MCT2 that binds to an intracellular site involving transmembrane helices 7-10. Biochem J 2010; 425: 523-30.
125. Simpson IA, Carruthers A, Vannucci SJ. Supply and demand in cerebral energy metabolism: the role of nutrient transporters. J Cereb Blood Flow Metab 2007; 27: 1766-91.